[{"Assets_0_Q2_USD":11792200000.0,"CommonStockDividendsPerShareDeclared_1_Q2_USD":0.16,"CommonStockDividendsPerShareDeclared_2_Q2_USD":0.32,"CommonStockSharesOutstanding_0_Q2_shares":142600000.0,"EarningsPerShareBasic_1_Q2_USD":-0.49,"EarningsPerShareBasic_2_Q2_USD":0.01,"EarningsPerShareDiluted_1_Q2_USD":-0.49,"EarningsPerShareDiluted_2_Q2_USD":0.01,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":285300000.0,"NetIncomeLoss_1_Q2_USD":-69600000.0,"NetIncomeLoss_2_Q2_USD":2000000.0,"StockholdersEquity_0_Q2_USD":6081200000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q2_shares":143300000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_2_Q2_shares":143600000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q2_shares":143300000.0,"WeightedAverageNumberOfSharesOutstandingBasic_2_Q2_shares":143300000.0,"Ticker":"PRGO","CIK":"1585364","name":"PERRIGO CO PLC","OfficialName":"Perrigo Company plc Ordinary Shares","form":"10-Q","period":"20170630","fy":"2017.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"4754722726.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NYSE","SP500":"nan","filed":"20170810"}]